Biomarker-stratified efficacy and safety of biologics in systemic lupus erythematosus: a systematic review and meta-analysis.

Lupus Sci Med · 2026 · PMC12983822 · PMID 41813059

Europe PMC DOI

hedged sentence

0.0550

closest p · 1.1× alpha

0.0550

boldest claim

The sentences

borderline significantp=0.055so close (0.05 < p ≤ 0.1)

Treatment discontinuations due to adverse events showed a borderline significant reduction (7.3% vs 8.2%; RR 0.87, 95% CI 0.75 to 1.00, p=0.055, I2=13.6%).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.